Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
Partner
Pirozzolo, Jack W.
Partner

Related Blogs

Capabilities

Suggested News & Insights

DOJ Releases FOCUS Questionnaire to Assist in Evaluating Qui Tams Filed by Data MinersJuly 20, 2026
Original Source
June DOJ/SBA FCA Settlement Highlights Continued Focus on Contractor ComplianceJuly 15, 2026
Original Source
Texas Supreme Court Imposes Materiality Requirement on Texas Healthcare Fraud Omissions ClaimsJuly 7, 2026
Original Source
Texas AG Secures Nearly $34 Million Settlement with Pharmaceutical Company, Reinforcing Active Ongoing THFPA EnforcementJuly 6, 2026
Original Source
HHS-OIG Decertifies New York Medicaid Fraud Control Unit, Escalating Federal Scrutiny of State Medicaid Fraud EnforcementJuly 6, 2026
Original Source
In House Hearing, DAAG Jenny Discusses FCA Enforcement Priorities Related to Grants, Faces Questioning on Using FCA to Target DiscriminationJune 29, 2026
Original Source